Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.

@article{Hsu2017SafetyAA,
  title={Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.},
  author={Chiun Yu Hsu and Se-Hoon Lee and Samuel Ejadi and Caroline Even and Roger B. Cohen and Christophe Le Tourneau and Janice M Mehnert and Alain P Algazi and Emilie M.J. van Brummelen and Sanatan Saraf and Pradeep Thanigaimani and Jonathan D. Cheng and Aaron R Hansen},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2017},
  volume={35 36},
  pages={4050-4056}
}
Purpose To establish the safety profile and antitumor activity of the anti-programmed death 1 receptor monoclonal antibody, pembrolizumab, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) that expressed programmed death-ligand 1 (PD-L1). Patients and Methods KEYNOTE-028 (NCT02054806) is a nonrandomized, multicohort, phase Ib trial of pembrolizumab in patients with PD-L1-positive advanced solid tumors. Key eligibility criteria for the NPC cohort included unresectable or… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 17 times over the past 90 days. VIEW TWEETS
8 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…